| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,390,000 |
| Market
Cap: |
23.10(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.18 - $6.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Biostage is a biotechnology company developing bioengineered organ implants based on its Cellframe™ and and Cellspan™ technology. Co.'s technology is comprised of a biocompatible scaffold, which is the foundation of its Cellframe™ technology, that is seeded with the patient's own mesenchymal stromal cells to form its Cellspan™ implant. Co.'s platform technology is being developed to treat life-threatening conditions of the esophagus, bronchus and trachea. Products being developed based on its technology for those indications are called Cellspan™ products. Co.'s primary research and development activities are focused in three areas: materials science, cell biology and engineering.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
5,100 |
24,864 |
175,878 |
| Total Buy Value |
$0 |
$24,885 |
$113,394 |
$1,012,397 |
| Total People Bought |
0 |
1 |
2 |
4 |
| Total Buy Transactions |
0 |
3 |
7 |
11 |
| Total Shares Sold |
0 |
0 |
0 |
134,295 |
| Total Sell Value |
$0 |
$0 |
$0 |
$962,849 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
4 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  La Francesca Saverio |
Chief Medical Officer |
• – – |
2015-08-28 |
4/A |
B |
$0.96 |
$2,400 |
D/D |
2,500 |
24,498 |
2.66 |
- |
|
| La Francesca Saverio |
Chief Medical Officer |
• – – |
2015-08-28 |
4 |
B |
$0.96 |
$2,400 |
D/D |
2,500 |
14,214 |
2.66 |
- |
|
| Mcnaughton Thomas |
Chief Financial Officer |
• – – |
2015-08-26 |
4 |
B |
$0.88 |
$8,800 |
D/D |
10,000 |
166,128 |
2.74 |
- |
|
| Kennedy John F |
Director |
– • – |
2015-08-24 |
4 |
B |
$0.83 |
$9,960 |
D/D |
12,000 |
26,724 |
2.39 |
- |
|
| Mcnaughton Thomas |
Chief Financial Officer |
• – – |
2015-08-21 |
4 |
B |
$0.76 |
$19,000 |
D/D |
25,000 |
156,128 |
2.74 |
- |
|
| Mcgorry James Joseph |
President and CEO |
• • – |
2015-08-21 |
4 |
B |
$0.75 |
$19,725 |
D/D |
26,300 |
61,300 |
2.81 |
- |
|
| Mcgorry James Joseph |
President and CEO |
• • – |
2015-08-20 |
4 |
B |
$0.66 |
$3,300 |
D/D |
5,000 |
35,000 |
2.73 |
- |
|
| Mcnaughton Thomas |
Chief Financial Officer |
• – – |
2015-08-19 |
4 |
B |
$0.62 |
$46,500 |
D/D |
75,000 |
131,128 |
2.74 |
- |
|
| La Francesca Saverio |
Chief Medical Officer |
• – – |
2015-06-30 |
4 |
A |
$1.22 |
$12,546 |
D/D |
10,284 |
21,998 |
|
- |
|
| Kennedy John F |
Director |
– • – |
2015-06-04 |
4 |
B |
$2.13 |
$2,130 |
D/D |
1,000 |
14,724 |
2.31 |
- |
|
| Green David |
Director |
– • – |
2015-06-03 |
4 |
B |
$1.98 |
$46,332 |
D/D |
23,400 |
288,259 |
2.39 |
- |
|
| Kennedy John F |
Director |
– • – |
2015-06-03 |
4 |
B |
$1.95 |
$1,950 |
D/D |
1,000 |
13,724 |
2.31 |
- |
|
| Mcnaughton Thomas |
Interim CEO & CFO |
• – – |
2015-06-03 |
4 |
B |
$2.01 |
$10,050 |
D/D |
5,000 |
56,128 |
2.74 |
- |
|
| Mcgorry James Joseph |
President and CEO |
• • – |
2015-06-02 |
4 |
B |
$1.90 |
$38,000 |
D/D |
20,000 |
30,000 |
2.81 |
- |
|
| Mcnaughton Thomas |
Interim CEO & CFO |
• – – |
2015-06-02 |
4 |
B |
$1.80 |
$14,400 |
D/D |
8,000 |
51,128 |
2.74 |
- |
|
| Green David |
Director |
– • – |
2015-06-02 |
4 |
B |
$1.81 |
$48,146 |
D/D |
26,600 |
264,859 |
2.39 |
- |
|
| Mcnaughton Thomas |
Interim CEO & CFO |
• – – |
2015-06-01 |
4 |
B |
$1.74 |
$5,220 |
D/D |
3,000 |
43,128 |
2.74 |
- |
|
| Kennedy John F |
Director |
– • – |
2015-06-01 |
4 |
B |
$1.67 |
$16,700 |
D/D |
10,000 |
12,724 |
2.39 |
- |
|
| Mcnaughton Thomas |
Interim CEO & CFO |
• – – |
2015-05-29 |
4 |
B |
$1.91 |
$9,550 |
D/D |
5,000 |
40,128 |
2.74 |
- |
|
| La Francesca Saverio |
Chief Medical Officer |
• – – |
2015-05-29 |
4 |
B |
$1.85 |
$9,250 |
D/D |
5,000 |
11,714 |
2.74 |
- |
|
| La Francesca Saverio |
Chief Medical OfficerOfficer |
• – – |
2015-04-29 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
6,714 |
|
- |
|
| Green David |
Chief Executive Officer |
• • – |
2015-02-18 |
4 |
B |
$1.75 |
$87,500 |
D/D |
50,000 |
388,259 |
2.81 |
- |
|
| Mcnaughton Thomas |
Chief Financial Officer |
• – – |
2015-02-13 |
4 |
B |
$2.91 |
$10,185 |
D/D |
3,500 |
35,128 |
2.74 |
- |
|
| Mcnaughton Thomas |
Chief Financial Officer |
• – – |
2015-02-12 |
4 |
B |
$2.59 |
$27,195 |
D/D |
10,500 |
31,628 |
2.74 |
- |
|
| Kennedy John F |
Director |
– • – |
2014-05-29 |
4 |
OE |
$4.75 |
$660 |
D/D |
139 |
2,724 |
|
- |
|
100 Records found
|
|
Page 4 of 4 |
|
|
0.02 (0.82%) 
